ICU Medical (NASDAQ:ICUI) and FRESENIUS SE &/S (OTCMKTS:FSNUY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
Volatility and Risk
ICU Medical has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, FRESENIUS SE &/S has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.
74.3% of ICU Medical shares are held by institutional investors. Comparatively, 0.1% of FRESENIUS SE &/S shares are held by institutional investors. 12.5% of ICU Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares ICU Medical and FRESENIUS SE &/S’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ICU Medical||$1.29 billion||4.21||$68.64 million||$5.52||48.15|
|FRESENIUS SE &/S||$38.28 billion||1.11||$2.05 billion||$0.92||20.85|
FRESENIUS SE &/S has higher revenue and earnings than ICU Medical. FRESENIUS SE &/S is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for ICU Medical and FRESENIUS SE &/S, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|FRESENIUS SE &/S||1||0||0||0||1.00|
This table compares ICU Medical and FRESENIUS SE &/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|FRESENIUS SE &/S||5.37%||8.76%||3.52%|
FRESENIUS SE &/S pays an annual dividend of $0.15 per share and has a dividend yield of 0.8%. ICU Medical does not pay a dividend. FRESENIUS SE &/S pays out 16.3% of its earnings in the form of a dividend.
ICU Medical beats FRESENIUS SE &/S on 9 of the 13 factors compared between the two stocks.
About ICU Medical
ICU Medical, Inc. develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave, and NanoClave brands; Neutron catheter patency connectors; SwabCap disinfecting caps; Tego hemodialysis connectors; NovaCath and SuperCath peripheral intravenous (IV) catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV solutions, such as normal salines, ringers, etc., which are used to replenish fluids and electrolytes; irrigation solutions to hydrate the wound, remove deep debris, assist with visual examination, to prevent infection, and improve healing; and nutritional solutions that feed vitamins, minerals, and other natural therapeutic substances directly into the blood stream. In addition, the company offers infusion pumps under the Plum 360, LifeCare PCA, SapphirePlus, and Sapphire names; Cogent 2-in-1 and LiDCO LX1 hemodynamic monitoring systems; CardioFlo hemodynamic monitoring sensors; TriOx PICC invasive venous oximetry sensors; SafeSet closed blood sampling and conservation systems; Transpac consumable blood pressure transducers; and Q2 Plus continuous cardiac output/oximetry systems. The company sells its products primarily to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
About FRESENIUS SE &/S
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.